

# Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic.

**Title:** Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic.

**Publication year:** 2021

**Journal:** The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

**Authors:** Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.

**Society:** European Respiratory Society

**Origin country:** International (Europe)

**Target countries:** Europe

**DOI:** 10.5152/tjg.2021.280721

**PMID:** 34405814

**Source:** <https://pubmed.ncbi.nlm.nih.gov/34405814/>

Turk J Gastroenterol Turk J Gastroenterol 3555 turkjgastro 9515841 The Turkish Journal of Gastroenterology 1300-4948 2148-5607 Turkish Society of Gastroenterology PMC8975298 PMC8975298.1 8975298 8975298 34405814 10.5152/tjg.2021.280721 tjg-32-6-488 1 Position Statement Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic Törüner Murat 1 Hakk■ Kalkan ■smaail 2 Akyüz Filiz 3 Tezel Ahmet 4 Ferhat Çelik Aykut 5 1 Department of Gastroenterology , Ankara University School of Medicine, Ankara, Turkey 2 Department of Gastroenterology , TOBB University of Economics and Technology School of Medicine, Ankara, Turkey 3 Department of Gastroenterology , ■stanbul University ■stanbul School of Medicine, ■stanbul, Turkey 4 Department of Gastroenterology , Trakya University School of Medicine, Edirne, Turkey 5 Department of Gastroenterology , ■stanbul University-Cerrahpa■a, Cerrahpa■a School of Medicine, ■stanbul, Turkey Corresponding author: Murat Törüner, e-mail: murattoruner@yahoo.com Cite this article as: Törüner M, Kalkan ■H, Akyüz F, Tezel A, Çelik AF. Turkish IBD organization's position statement on inflammatory bowel disease management recommendations during COVID-19 pandemic. Turk J Gastroenterol. 2021; 32 (6): 488 - 492 .

**Conflict of Interest:** The authors have no conflict of interest to declare.

6 2021 01 6 2021 32 6 404483 488 492 1 5 2021 7 5 2020 01 06 2021 14 04 2022 25 08 2024 © Copyright 2021 by The Turkish Society of Gastroenterology 2021 Turkish Society of Gastroenterology The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic.